Explicit|||389..400|3,0,1,1,2,0;3,0,1,1,2,1;3,0,1,1,2,2,0,0|in order to|||in order to|||Purpose.Goal|||||||||||245..388|3,0,0;3,0,1,0;3,0,1,1,0;3,0,1,1,1|The effects of 17β-oestradiol and of testosterone were tested on the cultured human monocytic/macrophage cell line (THP-1) activated with IFN-γ||||||||401..459|3,0,1,1,2,2,0,1|investigate their role in cell proliferation and apoptosis|||||||||||||
Explicit|||1370..1377|10,0,0,0|However|||however|||Contrast|||||||||||1115..1368|9,0|Increased poly-ADP ribose polymerase-cleaved expression and decreased proliferating cell nuclear antigen expression, as well as an increase of IκB-α and a decrease of the IκB-α phosphorylated form (ser 32), were found in testosterone-treated THP-1 cells||||||||1379..1458|10,0,2;10,0,3|the NF-κB DNA binding was found increased in 17β-oestradiol-treated THP-1 cells|||||||||||||
Explicit|||1766..1769|13,0,2|and|||and|||Conjunction|||||||||||1718..1764|13,0,0|Androgens were found to increase the apoptosis||||||||1770..1820|13,0,3,0,0;13,0,3,1,0;13,0,3,1,1,0;13,0,3,1,1,1,0;13,0,3,1,1,1,1,0|oestrogens showed a protective trend on cell death|||||||||||||
Explicit|||2100..2106|16,0,0,0|Indeed|||indeed|||Reinforcement|||||||||||1990..2098|15,0,1,1;15,0,1,2,0;15,0,1,2,1,0;15,0,1,2,1,1,0;15,0,1,2,1,1,1,0;15,0,1,2,1,1,1,1,0;15,0,1,2,1,1,1,1,1;15,0,1,2,1,1,1,1,2,0;15,0,1,2,1,1,1,1,2,1,0;15,0,1,2,1,1,1,1,2,1,1,0;15,0,1,2,1,1,1,1,2,1,1,1,0;15,0,1,2,1,1,1,1,2,1,1,1,1;15,0,1,2,1,1,1,1,2,1,1,1,2;15,0,1,2,1,1,1,1,2,1,1,1,3|and suggests that gonadal steroids may play an important role in the regulation of the immune response [1-4]||||||||2108..2280|16,0,2;16,0,3,0;16,0,3,1,0;16,0,3,1,1,0;16,0,3,1,1,1,0,0;16,0,3,1,1,1,0,1,0;16,0,3,1,1,1,0,1,1,0;16,0,3,1,1,1,0,1,1,1;16,0,3,1,1,1,0,1,1,2,0;16,0,3,1,1,1,0,1,1,2,1;16,0,3,1,1,1,0,1,1,2,2,0;16,0,3,1,1,1,0,1,1,2,2,1;16,0,3,1,1,1,0,1,1,2,2,2;16,0,3,1,1,1,0,1,1,2,2,3;16,0,3,1,1,1,0,1,1,2,2,1;16,0,3,1,1,1,0,1,1,2,2,5,0;16,0,3,1,1,1,0,1,1,2,2,1;16,0,3,1,1,1,0,1,1,2,2,7,0;16,0,3,1,1,1,0,1,1,2,2,7,1|many cells of the immune system have been found to possess functional sex hormone receptors, such as CD8-positive T cells, B cells and, notably, monocytes/macrophages [5,6]|||||||||||||
Explicit|||2284..2293|17,0,0,0|Therefore|||therefore|||Restatement.Specification|||||||||||1886..2098|15,0,0;15,0,1,0;15,0,1,1;15,0,1,2,0;15,0,1,2,1,0;15,0,1,2,1,1,0;15,0,1,2,1,1,1,0;15,0,1,2,1,1,1,1,0;15,0,1,2,1,1,1,1,1;15,0,1,2,1,1,1,1,2,0;15,0,1,2,1,1,1,1,2,1,0;15,0,1,2,1,1,1,1,2,1,1,0;15,0,1,2,1,1,1,1,2,1,1,1,0;15,0,1,2,1,1,1,1,2,1,1,1,1;15,0,1,2,1,1,1,1,2,1,1,1,2;15,0,1,2,1,1,1,1,2,1,1,1,3|Experimental and clinical evidence indicates that immune reactivity is greater in females than in males and suggests that gonadal steroids may play an important role in the regulation of the immune response [1-4]||||||||2295..2675|17,0,2;17,0,3,0;17,0,3,1,0;17,0,3,1,1,0,0;17,0,3,1,1,0,1;17,0,3,1,1,0,2;17,0,3,1,1,0,3;17,0,3,1,1,0,4,0;17,0,3,1,1,0,4,1,0;17,0,3,1,1,0,4,1,1;17,0,3,1,1,0,4,1,2,0;17,0,3,1,1,0,4,1,2,1,0;17,0,3,1,1,0,4,1,2,1,1;17,0,3,1,1,0,4,1,2,1,2;18,0,0,0;18,0,1,0;18,0,1,1,0;19,0,0;19,0,1,0;19,0,2,0;19,0,2,1;19,0,2,2,0,0;19,0,2,2,1,0,0;19,0,2,2,1,0,1,0;19,0,2,2,1,0,1,1,0;19,0,2,2,1,0,1,1,1;19,0,2,2,1,0,1,1,2|17β-oestradiol (E2) was found to inhibit cellular apoptosis, to increase antibody production by B cells and to exert dose-related effects on T-cell functions [7]. Androgens seem to exert effects opposite to those of E2 on immune response [8]. Clinical epidemiology clearly confirms a higher prevalence of autoimmune diseases in female subjects when compared with male subjects [9]|||||||||||||
Explicit|||2877..2885|20,0,1,1,3,0|although|||although|||Concession.Contra-expectation|||||||||||2679..2875|20,0,0;20,0,1,0;20,0,1,1,0;20,0,1,1,1,0|The studies concerning the functional interaction between the NF-κB pathway and members of the steroid hormone receptor family, and their role in synovial inflammation, have advanced significantly||||||||2886..2920|20,0,1,1,3,1,0|with controversial results [10,11]|||||||||||||
Explicit|||2922..2935|21,0|In particular|||in particular|||Restatement.Specification|||||||||||2877..2920|20,0,1,1,3,0;20,0,1,1,3,1,0|although with controversial results [10,11]||||||||2937..3498|21,2;21,1;21,4;21,5;22,0;22,1,0;22,1,1,0;22,1,1,1,0;22,1,1,1,1;22,1,1,1,0;22,1,1,1,3;22,1,1,1,4;23,0,0;23,0,1;23,0,2;23,0,3|after binding with E2, oestrogen receptors have been shown to interact with NF-κB factors, via transcriptional co-factors, resulting in mutual or non-mutual antagonism. Other studies hypothesize that, since oestrogen receptors may repress both constitutive and inducible NF-κB activity, the overexpression of NF-κB-inducible genes in oestrogen receptor-negative cells might contribute to malignant cell growth and chemotherapeutic resistance [12,13]. On the contrary, further studies report that E2 blocks the transcriptional activity of p65 in macrophages [14]|||||||||||||
Explicit|||2937..2942|21,2,0|after|||after|||Temporal.Succession|||||||||||2922..2935;2960..3104|21,0;21,4;21,5|In particular oestrogen receptors have been shown to interact with NF-κB factors, via transcriptional co-factors, resulting in mutual or non-mutual antagonism||||||||2943..2958|21,2,1,0|binding with E2|||||||||||||
Explicit|||3138..3143|22,1,1,1,1,0|since|||since|||Cause.Reason|||||||||||3224..3386|22,1,1,1,3;22,1,1,1,4|the overexpression of NF-κB-inducible genes in oestrogen receptor-negative cells might contribute to malignant cell growth and chemotherapeutic resistance [12,13]||||||||3144..3222|22,1,1,1,1,1|oestrogen receptors may repress both constitutive and inducible NF-κB activity|||||||||||||
Explicit|||3388..3403|23,0,0|On the contrary|||on the contrary|||Contrast|||||||||||2922..3386|21,0;21,1;21,2;21,1;21,4;21,5;22,0;22,1,0;22,1,1,0;22,1,1,1,0;22,1,1,1,1;22,1,1,1,0;22,1,1,1,3;22,1,1,1,4|In particular, after binding with E2, oestrogen receptors have been shown to interact with NF-κB factors, via transcriptional co-factors, resulting in mutual or non-mutual antagonism. Other studies hypothesize that, since oestrogen receptors may repress both constitutive and inducible NF-κB activity, the overexpression of NF-κB-inducible genes in oestrogen receptor-negative cells might contribute to malignant cell growth and chemotherapeutic resistance [12,13]||||||||3405..3498|23,0,2;23,0,3|further studies report that E2 blocks the transcriptional activity of p65 in macrophages [14]|||||||||||||
Explicit|||3500..3507|24,0,0,0|However|||however|||Concession.Contra-expectation|||||||||||2877..2920|20,0,1,1,3,0;20,0,1,1,3,1,0|although with controversial results [10,11]||||||||3509..3926|24,0,2;24,0,3,0;24,0,3,1,0,0;24,0,3,1,0,1,0;24,0,3,1,0,1,1;24,0,3,1,0,1,2,0;24,0,3,1,0,1,2,1;24,0,3,1,0,1,2,2;24,0,3,1,0,1,2,3,0;25,0;25,1;25,2;25,3,0;25,3,1,0;25,3,1,1,0;25,3,1,1,1;25,3,1,1,2,0;25,3,1,1,2,1;25,3,1,1,2,2,0,0;25,3,1,1,2,2,1;25,3,1,1,2,2,2,0;25,3,1,1,2,2,2,1,0;25,3,1,1,2,2,2,1,1|these opposite observations arise using different cell lines (human/animals) and culture conditions as well as different hormone concentrations [15]. In addition, multiple mechanisms concerning the interaction between oestrogen receptors and NF-κB have been proposed, such as repression of NF-κB DNA binding by physical association with oestrogen receptors and the regulation of IκB-α expression by oestrogens [16,17]|||||||||||||
Explicit|||3659..3670|25,0|In addition|||in addition|||Conjunction|||||||||||3500..3657|24,0,0,0;24,0,1;24,0,2;24,0,3,0;24,0,3,1,0,0;24,0,3,1,0,1,0;24,0,3,1,0,1,1;24,0,3,1,0,1,2,0;24,0,3,1,0,1,2,1;24,0,3,1,0,1,2,2;24,0,3,1,0,1,2,3,0|However, these opposite observations arise using different cell lines (human/animals) and culture conditions as well as different hormone concentrations [15]||||||||3672..3926|25,2;25,3,0;25,3,1,0;25,3,1,1,0;25,3,1,1,1;25,3,1,1,2,0;25,3,1,1,2,1;25,3,1,1,2,2,0,0;25,3,1,1,2,2,1;25,3,1,1,2,2,2,0;25,3,1,1,2,2,2,1,0;25,3,1,1,2,2,2,1,1|multiple mechanisms concerning the interaction between oestrogen receptors and NF-κB have been proposed, such as repression of NF-κB DNA binding by physical association with oestrogen receptors and the regulation of IκB-α expression by oestrogens [16,17]|||||||||||||
Explicit|||4200..4212|27,2,0,0|consequently|||consequently|||Cause.Claim|||||||||||3930..4198|26,0;27,0|The androgen receptor seems to be closely related to the glucocorticoid receptor in terms of both structure and sequence homology. The androgen receptor and the glucocorticoid receptor have been shown to interact and repress activator protein 1 via a similar mechanism||||||||4214..4377|27,2,2,0;27,2,3,0;27,2,3,1;27,2,3,2,0;27,2,3,2,1,0;27,2,3,2,2,0;27,2,3,2,2,1,0;27,2,3,2,2,1,1,0;27,2,3,2,2,1,1,1,0;27,2,3,2,2,1,1,2,0;27,2,3,2,2,1,1,2,1;27,2,3,2,2,1,1,2,2,0;27,2,3,2,2,1,1,2,2,1,0;27,2,3,2,2,1,1,2,2,1,1|it would not be surprising that the androgen receptor might also interact with NF-κB in a manner very similar to that observed for the glucocorticoid receptor [18]|||||||||||||
Explicit|||4659..4662|29,0,2|and|||and|||Continuation|||||||||||4544..4657|29,0,0|It is possible that inflammatory agents that activate NF-κB in vivo may interfere with normal androgen signalling||||||||4663..4781|29,0,3,0;29,0,3,1,0;29,0,3,1,1,0;29,0,3,1,1,1,0;29,0,3,1,1,1,1,0;29,0,3,1,1,1,1,1,0;29,0,3,1,1,1,1,1,1|recent studies indicate that the androgen receptor and NF-κB (subunit p65) are mutual transcriptional antagonists [20]|||||||||||||
Explicit|||4805..4814|30,0,1,1,0|therefore|||therefore|||Cause.Result|||||||||||4544..4781|29,0,0;29,0,1;29,0,2;29,0,3,0;29,0,3,1,0;29,0,3,1,1,0;29,0,3,1,1,1,0;29,0,3,1,1,1,1,0;29,0,3,1,1,1,1,1,0;29,0,3,1,1,1,1,1,1|It is possible that inflammatory agents that activate NF-κB in vivo may interfere with normal androgen signalling, and recent studies indicate that the androgen receptor and NF-κB (subunit p65) are mutual transcriptional antagonists [20]||||||||4783..4804;4815..5038|30,0,0;30,0,1,0;30,0,1,2|The present study was undertaken to examine the long-term (time course of 7 days) effects of sex hormones on activated cultured human monocytic/macrophage cell line (THP-1) cells by investigating their effects on cell proliferation and apoptosis|||||||||||||
Explicit|||4826..4828|30,0,1,2,1,0,0|to|||to|||Purpose.Goal|||||||||||4783..4825|30,0,0;30,0,1,0;30,0,1,1,0;30,0,1,2,0|The present study was therefore undertaken||||||||4829..4971|30,0,1,2,1,0,1,0;30,0,1,2,1,0,1,1|examine the long-term (time course of 7 days) effects of sex hormones on activated cultured human monocytic/macrophage cell line (THP-1) cells|||||||||||||
Explicit|||4972..4974|30,0,1,2,1,0,1,2,0|by|||by|||Purpose.Enablement|||||||||||4826..4971|30,0,1,2,1,0,0;30,0,1,2,1,0,1,0;30,0,1,2,1,0,1,1|to examine the long-term (time course of 7 days) effects of sex hormones on activated cultured human monocytic/macrophage cell line (THP-1) cells||||||||4975..5038|30,0,1,2,1,0,1,2,1,0|investigating their effects on cell proliferation and apoptosis|||||||||||||
Explicit|||5234..5247|32,0|In particular|||in particular|||Restatement.Specification|||||||||||4783..5038|30,0|The present study was therefore undertaken to examine the long-term (time course of 7 days) effects of sex hormones on activated cultured human monocytic/macrophage cell line (THP-1) cells by investigating their effects on cell proliferation and apoptosis||||||||5249..5541|32,2;32,3,0;32,4,0;32,4,1,0;32,4,1,1,0,0;32,4,1,1,1,0,0;32,4,1,1,1,0,1,0;32,4,1,1,1,0,1,1,0;32,4,1,1,1,0,1,2,0;32,4,1,1,1,0,1,2,1,0;32,4,1,1,1,0,1,2,1,1,0;32,4,1,1,1,0,1,2,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,1,1,1;33,0,0,0;33,0,1;33,0,2;33,0,3|in the present study we used pharmacological concentrations of E2 (final concentration, 10 nM; Sigma-Aldrich, Milan, Italy) that have been already described as the most efficient in stimulating macrophages in vitro [22]. Accordingly, the same concentration has been used for testosterone [23]|||||||||||||
Explicit|||5470..5481|33,0,0,0|Accordingly|||accordingly|||Cause.Result|||||||||||5234..5468|32,0;32,1;32,2;32,3,0;32,4,0;32,4,1,0;32,4,1,1,0,0;32,4,1,1,1,0,0;32,4,1,1,1,0,1,0;32,4,1,1,1,0,1,1,0;32,4,1,1,1,0,1,2,0;32,4,1,1,1,0,1,2,1,0;32,4,1,1,1,0,1,2,1,1,0;32,4,1,1,1,0,1,2,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,1,1,0;32,4,1,1,1,0,1,2,1,1,1,1,1,1,1|In particular, in the present study we used pharmacological concentrations of E2 (final concentration, 10 nM; Sigma-Aldrich, Milan, Italy) that have been already described as the most efficient in stimulating macrophages in vitro [22]||||||||5483..5541|33,0,2;33,0,3|the same concentration has been used for testosterone [23]|||||||||||||
Explicit|||5548..5557|34,0,1,0|therefore|||therefore|||Restatement.Generalization|||||||||||4544..5038|29,0,0;29,0,1;29,0,2;29,0,3,0;29,0,3,1,0;29,0,3,1,1,0;29,0,3,1,1,1,0;29,0,3,1,1,1,1,0;29,0,3,1,1,1,1,1,0;29,0,3,1,1,1,1,1,1;30,0|It is possible that inflammatory agents that activate NF-κB in vivo may interfere with normal androgen signalling, and recent studies indicate that the androgen receptor and NF-κB (subunit p65) are mutual transcriptional antagonists [20]. The present study was therefore undertaken to examine the long-term (time course of 7 days) effects of sex hormones on activated cultured human monocytic/macrophage cell line (THP-1) cells by investigating their effects on cell proliferation and apoptosis||||||||5545..5547;5558..5687|34,0,0,0;34,0,2|We investigated sex hormone effects on the NF-κB pathway, as a complex of molecules modulating cellular responses in activated cells|||||||||||||
Explicit|||5926..5934|37,0,0|Moreover|||moreover|||Conjunction|||||||||||5714..5924|36,0,0;36,0,1,0;36,0,1,1,0;36,0,1,1,1,0;36,0,1,1,1,1,0;36,0,1,1,1,1,1,0;36,0,1,1,1,1,1,1,0;36,0,1,1,1,1,1,1,1,0;36,0,1,1,1,1,1,1,1,1,0;36,0,1,1,1,1,1,1,1,1,1|THP-1 cells (Interlab cell line collection HTL097014; IST c/o CBA, Genoa, Italy) were cultured in RPMI-1640 medium supplemented with 2% foetal bovine serum (Sigma-Aldrich) (5% CO2 humidified atmosphere at 37°C)||||||||5936..6124|37,2;37,3|the absence of binding of the hormones with other foetal bovine serum components related to growth rate and the survival of cultured THP-1 cells over the course of 7 days were investigated|||||||||||||
Explicit|||6288..6295|40,0,0,0|Briefly|||briefly|||Restatement.Specification|||||||||||6201..6286|39,0|The viability of the cells (97–98%) was tested by the Trypan blue exclusion procedure||||||||6297..6735|40,0,2;40,0,3,0;40,0,3,1;40,0,3,2,0;40,0,3,2,1,0;40,0,3,2,1,1;40,0,3,2,1,2,0;40,0,3,2,1,2,1;40,0,3,2,1,2,2,0,0;40,0,3,2,1,2,2,0,1,0;40,0,3,2,1,2,2,0,1,1,0;40,0,3,2,1,2,2,0,1,2,0;40,0,3,2,1,2,2,0,1,2,1,0;40,0,3,2,1,2,2,0,1,2,1,1;40,0,3,2,1,2,2,0,1,2,1,2;41,0;42,0,0;42,0,1,0;42,0,1,1,0;42,0,1,2,0;42,0,1,2,1;42,0,1,2,2,0;42,0,1,2,2,1,0;42,0,1,2,2,1,1,0;42,0,1,2,2,1,1,1|the cells were seeded into six-well flat-bottom plates (106 cells/well) and were treated with 500 U/ml IFN-γ (Sigma-Aldrich) in order to differentiate THP-1 into macrophage cells [24]. The activation and transformation of the cells was evaluated by the expression of different macrophage antigens: CD68, CD14, HAM 56, Mac 387. The THP-1 activated cells were then incubated for 24, 48, 72, 96 and 168 hours with E2 and testosterone (10 nM)|||||||||||||
Explicit|||6422..6433|40,0,3,2,1,2,0;40,0,3,2,1,2,1;40,0,3,2,1,2,2,0,0|in order to|||in order to|||Purpose.Goal|||||||||||6369..6421|40,0,3,1;40,0,3,2,0;40,0,3,2,1,0;40,0,3,2,1,1,0;40,0,3,2,1,1,1,0;40,0,3,2,1,1,1,1,0;40,0,3,2,1,1,1,1,1,0|and were treated with 500 U/ml IFN-γ (Sigma-Aldrich)||||||||6434..6480|40,0,3,2,1,2,2,0,1,0;40,0,3,2,1,2,2,0,1,1,0;40,0,3,2,1,2,2,0,1,2,0;40,0,3,2,1,2,2,0,1,2,1,0;40,0,3,2,1,2,2,0,1,2,1,1;40,0,3,2,1,2,2,0,1,2,1,2|differentiate THP-1 into macrophage cells [24]|||||||||||||
Explicit|||6655..6659|42,0,1,1,0|then|||then|||Temporal.Precedence|||||||||||6482..6622|41,0|The activation and transformation of the cells was evaluated by the expression of different macrophage antigens: CD68, CD14, HAM 56, Mac 387||||||||6624..6654;6660..6735|42,0,0;42,0,1,0;42,0,1,2,0;42,0,1,2,1;42,0,1,2,2,0;42,0,1,2,2,1,0;42,0,1,2,2,1,1,0;42,0,1,2,2,1,1,1|The THP-1 activated cells were incubated for 24, 48, 72, 96 and 168 hours with E2 and testosterone (10 nM)|||||||||||||
Explicit|||7114..7118|45,0,1,1,0|then|||then|||Temporal.Precedence|||||||||||6880..7091|44,0|At the end of the different incubation times, the cells were harvested, washed in Dulbecco's phosphate-buffered saline (DPBS) and treated with different lysis buffers for the nuclear and total protein extraction||||||||7093..7113;7119..7259|45,0,0;45,0,1,0;45,0,1,2|Part of the cell was collected for DNA content (normal and apoptotic) evaluation by flow analysis cytometry scatter analysis and for immunocytochemistry analysis|||||||||||||
Explicit|||7766..7773|49,0,0,0|Briefly|||briefly|||Restatement.Specification|||||||||||7469..7647|47,0|The cell growth was evaluated at different times by the methyl-tetrazolium salt test, which represents a quantitative colorimetric assay to detect cell survival and proliferation||||||||7775..7881|49,0,2;49,0,3|the cells were seeded into 96-well microtitre plates and were treated according to the experimental design|||||||||||||
Explicit|||8106..8122|51,0,0|Four hours later|||four hours later|||Temporal.Precedence|||||||||||7882..8104|50,0|At the established time, 50 μl methyl-tetrazolium salt labelling reagent [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5 mg/ml in PBS] was added to each well and incubated in humidified atmosphere at 37°C||||||||8124..8200|51,0,2;51,0,3|100 μl dimethylsulfoxide were introduced into each well and mixed thoroughly|||||||||||||
Explicit|||8698..8709|55,0,1,1,4,0;55,0,1,1,4,1;55,0,1,1,4,2,0,0|in order to|||in order to|||Purpose.Goal|||||||||||8493..8696|55,0,0;55,0,1,0;55,0,1,1,0;55,0,1,1,1;55,0,1,1,2,0;55,0,1,1,2,1,0;55,0,1,1,2,1,1,0;55,0,1,1,2,1,1,1|The apoptotic events were evaluated after 168 hours from both sex hormone stimulation and staurosporine treatment (17 nM for 24 hours) by annexin V-propidium iodide analysis (MBL Co., Ltd, Nagoya, Japan)||||||||8710..8849|55,0,1,1,4,2,0,1,0;55,0,1,1,4,2,0,1,1,0;55,0,1,1,4,2,0,1,1,1;55,0,1,1,4,2,0,1,1,2,0;55,0,1,1,4,2,0,1,1,2,1,0;55,0,1,1,4,2,0,1,1,2,1,1|detect the early-stage apoptosis (cells only annexin-positive) and the late-stage apoptosis (cells annexin-positive and propidium-positive)|||||||||||||
Explicit|||8851..8856|56,0,0|After|||after|||Temporal.Succession|||||||||||8925..8997|56,2;56,3|1 μl fluorescein-labelled annexin V and 1 μl propidium iodide were added||||||||8857..8923|56,0,1,0|resuspending the cells (1 × 105) into 200 μl of 1 x binding buffer|||||||||||||
Explicit|||8999..9003|57,0,0,0|Then|||then|||Temporal.Precedence|||||||||||8851..8997|56,0;56,1;56,2;56,3|After resuspending the cells (1 × 105) into 200 μl of 1 x binding buffer, 1 μl fluorescein-labelled annexin V and 1 μl propidium iodide were added||||||||9004..9071|57,0,1;57,0,2,0;57,0,2,1,0;57,0,2,1,1;57,0,2,1,2,0;57,0,2,1,2,1,0;57,0,2,1,2,1,1,0;57,0,2,1,2,1,1,1|the cells were incubated for 5 min at room temperature (dark light)|||||||||||||
Explicit|||9073..9080|58,0,0,0|Finally|||finally|||Temporal.Precedence|Conjunction||||||||||8999..9071|57,0,0,0;57,0,1;57,0,2,0;57,0,2,1,0;57,0,2,1,1;57,0,2,1,2,0;57,0,2,1,2,1,0;57,0,2,1,2,1,1,0;57,0,2,1,2,1,1,1|Then the cells were incubated for 5 min at room temperature (dark light)||||||||9082..9260|58,0,2;58,0,3|the cells were plated on glass slides and analysed by fluorescence microscopy (550 nm) for a total of 500 cells per sample, which allows detection even of a single apoptotic cell|||||||||||||
Explicit|||9262..9264|59,0,0,0,0|To|||to|||Purpose.Goal|||||||||||9331..9587|59,0,1;59,0,2,0;59,0,2,1;59,0,2,2,0;59,0,2,2,1,0;59,0,2,2,1,1,0;59,0,2,2,1,1,1,0;59,0,2,2,1,1,1,1,0;59,0,2,2,1,1,1,1,1,0;59,0,2,2,1,1,1,1,1,1|the cells stimulated with hormones, without and with staurosporine, after fixation were stained with intercalating dyes (propidium iodide) and were analysed by flow analysis cytometry scatter (Becton-Dickinson-Immunocytometry Systems, Erembodegem, Belgium)||||||||9265..9330|59,0,0,0,1,0;59,0,0,0,1,1,0;59,0,0,0,1,1,1,0;59,0,0,0,1,1,1,1|confirm the reduced DNA content (oligonucleosomal-size fragments)|||||||||||||
Explicit|||9399..9404|59,0,1,1,1,4,0|after|||after|||Temporal.Succession|||||||||||9331..9397;9414..9587|59,0,1,0;59,0,1,1,0;59,0,1,1,1,0;59,0,1,1,1,1;59,0,1,1,1,2;59,0,2,0;59,0,2,1;59,0,2,2,0;59,0,2,2,1,0;59,0,2,2,1,1,0;59,0,2,2,1,1,1,0;59,0,2,2,1,1,1,1,0;59,0,2,2,1,1,1,1,1,0;59,0,2,2,1,1,1,1,1,1|the cells stimulated with hormones, without and with staurosporine were stained with intercalating dyes (propidium iodide) and were analysed by flow analysis cytometry scatter (Becton-Dickinson-Immunocytometry Systems, Erembodegem, Belgium)||||||||9405..9413|59,0,1,1,1,4,1,0|fixation|||||||||||||
Explicit|||9737..9741|61,0,1,1,0|then|||then|||Temporal.Precedence|||||||||||9591..9720|60,0|THP-1 cells were harvested at a concentration of 5 × 103, being sedimented on poly-L-lysine-coated glass slides for 40 min at 4°C||||||||9722..9736;9742..10026|61,0,0;61,0,1,0;61,0,1,2;61,0,1,3;61,1;61,2;61,3,0,0;61,3,0,1;61,3,0,2,0;61,3,0,2,1,0;61,3,0,2,1,1,0;61,3,0,2,1,1,1,0;61,3,0,2,1,1,1,1;61,3,0,2,1,1,1,2;61,3,0,2,1,1,1,1;61,3,0,2,1,1,1,4,0;61,3,0,2,1,1,1,1;61,3,0,2,1,1,1,6,0;61,3,0,2,1,1,1,7;61,3,0,2,1,1,1,8,0;61,3,0,2,1,1,1,8,1,0;61,3,0,2,1,1,1,8,1,1|The spots were air-dried and fixed in cold acetone for 30 s, and stored at -20°C until the immunodetermination of poly-ADP ribose polymerase (PARP)-cleaved expression, proliferating cell nuclear antigen (PCNA) expression, NF-κB, IκB-α and IκB-α-ser 32 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)|||||||||||||
Explicit|||9808..9813|61,3,0,2,0|until|||until|||Temporal.Precedence|||||||||||9788..9807|61,2;61,3,0,0;61,3,0,1|and stored at -20°C||||||||9814..10026|61,3,0,2,1,0;61,3,0,2,1,1,0;61,3,0,2,1,1,1,0;61,3,0,2,1,1,1,1;61,3,0,2,1,1,1,2;61,3,0,2,1,1,1,1;61,3,0,2,1,1,1,4,0;61,3,0,2,1,1,1,1;61,3,0,2,1,1,1,6,0;61,3,0,2,1,1,1,7;61,3,0,2,1,1,1,8,0;61,3,0,2,1,1,1,8,1,0;61,3,0,2,1,1,1,8,1,1|the immunodetermination of poly-ADP ribose polymerase (PARP)-cleaved expression, proliferating cell nuclear antigen (PCNA) expression, NF-κB, IκB-α and IκB-α-ser 32 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)|||||||||||||
Explicit|||10028..10033|62,0,0,0|After|||after|||Temporal.Succession|||||||||||10054..10146|62,0,2,0;62,0,3|spots were incubated with the anti-human antibody at different dilutions at room temperature||||||||10034..10052|62,0,0,1|rehydration in PBS|||||||||||||
Explicit|||10305..10312|64,0,0,0,0|Briefly|||briefly|||Restatement.Specification|||||||||||10148..10303|63,0,0;63,0,1,0;63,0,1,1,0;63,0,1,1,1,0,0;63,0,1,1,1,0,1,0;63,0,1,1,1,0,1,1,0;63,0,1,1,1,0,1,1,1|The second and third steps were performed using the improved biotin-streptavidin-amplified detection system (Vector Laboratories Inc., Burlingame, CA, USA)||||||||10314..10971|64,0,0,2;64,0,0,1;64,0,0,4,0;64,0,0,5;64,0,1;64,0,2;65,0;65,1;65,2,0;65,3|according to this method, cells were incubated with the secondary antibody (biotinylated IgG, 1:20 dilution) for 20 min at room temperature and then, after several washes in PBS, cells were treated with the concentrated enzyme label (biotin-streptavidin-peroxidase) for 20 min and, finally, incubated at room temperature with the peroxidase-substrate solution (0.04% 3,3-diaminobenzidine [Sigma-Aldrich] in 50 mM Tris-HCl buffer containing 0.3% hydrogen peroxide) for 15 min. After rinsing with PBS, slides were counterstained with haematoxylin, were dried and cover slipped with Eukitt, and were examined by light microscopy and computerized image analysis|||||||||||||
Explicit|||10458..10462|64,0,2,0,0|then|||then|||Temporal.Precedence|||||||||||10305..10453|64,0,0|Briefly, according to this method, cells were incubated with the secondary antibody (biotinylated IgG, 1:20 dilution) for 20 min at room temperature||||||||10454..10457;10464..10788|64,0,1;64,0,2,2;64,0,2,1;64,0,2,4,0;64,0,2,5|and after several washes in PBS, cells were treated with the concentrated enzyme label (biotin-streptavidin-peroxidase) for 20 min and, finally, incubated at room temperature with the peroxidase-substrate solution (0.04% 3,3-diaminobenzidine [Sigma-Aldrich] in 50 mM Tris-HCl buffer containing 0.3% hydrogen peroxide) for 15 min|||||||||||||
Explicit|||10464..10469|64,0,2,2,0|after|||after|||Temporal.Succession|||||||||||10454..10462;10493..10788|64,0,1;64,0,2,0,0;64,0,2,4,0;64,0,2,5|and then cells were treated with the concentrated enzyme label (biotin-streptavidin-peroxidase) for 20 min and, finally, incubated at room temperature with the peroxidase-substrate solution (0.04% 3,3-diaminobenzidine [Sigma-Aldrich] in 50 mM Tris-HCl buffer containing 0.3% hydrogen peroxide) for 15 min||||||||10470..10491|64,0,2,2,1|several washes in PBS|||||||||||||
Explicit|||10596..10603|64,0,2,5,1,1,1,1,3,1,3,0|finally|||finally|||Temporal.Precedence|||||||||||10493..10590|64,0,2,4,0;64,0,2,5,0;64,0,2,5,1,0;64,0,2,5,1,1,0;64,0,2,5,1,1,1,0;64,0,2,5,1,1,1,1,0;64,0,2,5,1,1,1,1,1,0;64,0,2,5,1,1,1,1,2;64,0,2,5,1,1,1,1,3,0;64,0,2,5,1,1,1,1,3,1,0|cells were treated with the concentrated enzyme label (biotin-streptavidin-peroxidase) for 20 min||||||||10591..10594;10605..10788|64,0,2,5,1,1,1,1,3,1,1;64,0,2,5,1,1,1,1,3,1,5;64,0,2,5,1,1,1,1,2;64,0,2,5,1,2|and incubated at room temperature with the peroxidase-substrate solution (0.04% 3,3-diaminobenzidine [Sigma-Aldrich] in 50 mM Tris-HCl buffer containing 0.3% hydrogen peroxide) for 15 min|||||||||||||
Explicit|||10790..10795|65,0,0|After|||after|||Temporal.Succession|||||||||||10814..10971|65,2,0;65,3|slides were counterstained with haematoxylin, were dried and cover slipped with Eukitt, and were examined by light microscopy and computerized image analysis||||||||10796..10812|65,0,1|rinsing with PBS|||||||||||||
Explicit|||11008..11018|66,0,1,1,3,0;66,0,1,1,3,1,0|except for|||except for|||Exception|||||||||||10973..11006|66,0,0,0;66,0,1,0;66,0,1,1,0;66,0,1,1,1,0|Controls were treated identically||||||||11019..11063|66,0,1,1,3,1,1,0|omitting the primary or secondary antibodies|||||||||||||
Explicit|||11215..11218|68,0,1|and|||and|||Continuation|||||||||||11165..11214|68,0,0|For each sample, 100 cells were randomly analysed||||||||11219..11306|68,0,2|the pixels per micron square (positive area) were quantified by the Leica Q500 software|||||||||||||
Explicit|||11386..11390|69,0,1,1,2,0|then|||then|||Temporal.Precedence|||||||||||11308..11381|69,0,0;69,0,1,0;69,0,1,1,0|The single cells were randomly selected by the operators using the cursor||||||||11382..11385;11391..11434|69,0,1,1,1;69,0,1,1,2,1,0;69,0,1,1,2,2;69,0,1,1,2,3|and automatically measured as the positive area|||||||||||||
Explicit|||11496..11498|70,0,1,1,1,0,0|to|||to|||Purpose.Goal|||||||||||11436..11495|70,0,0;70,0,1,0;70,0,1,1,0|A constant optical threshold and filter combination was set||||||||11499..11529|70,0,1,1,1,0,1|select only the positive cells|||||||||||||
Explicit|||11626..11629|71,0,2|and|||and|||Continuation|||||||||||11533..11624|71,0,0,0;71,0,0,1,0;71,0,0,1,1,0;71,0,0,1,1,1,0;71,0,0,1,1,1,1,0;71,0,0,1,1,1,1,1,0;71,0,0,1,1,1,1,1,1,0;71,0,0,1,1,1,1,1,1,1,0;71,0,0,1,1,1,1,1,1,1,1|The results were analysed by the analysis of variance non-parametric test (Bonferroni test)||||||||11630..11685|71,0,3|the values are presented as means ± standard deviations|||||||||||||
Explicit|||12002..12012|75,0,1,0,1,0|thereafter|||thereafter|||Temporal.Precedence|||||||||||11918..11967|74,0|The surnatants were collected and stored at -80°C||||||||11971..12001;12013..12140|75,0,0;75,0,1,0,0;75,0,1,0,2;75,0,1,1;75,0,1,2,0;75,0,1,2,1,0;75,0,1,2,1,1;75,0,1,2,1,2,0;75,0,1,2,1,2,1,0;75,0,1,2,1,2,1,1,0;75,0,1,2,1,2,1,1,1|The samples of surnatants were diluted with reducing sample buffer and were separated by electrophoresis on a 10% SDS-PAGE gel (20 μg protein per lane loaded)|||||||||||||
Explicit|||12616..12623|79,0,0|Finally|||finally|||Temporal.Precedence|||||||||||12324..12614|78,0;78,1;78,2;78,3|For immunoblot analysis, the membranes were incubated with the different antibodies for 1 hour (NF-κB, IκB-α, IκB-α-ser 32, respectively; Santa Cruz Biotechnology) (dilution 1:200) in DPBS at room temperature with constant shaking, and were washed extensively in 0.05% DPBS/Tween 20, pH 7.4||||||||12625..12827|79,2;79,3|the membranes were incubated with secondary horseradish peroxidase-labelled polyclonal anti-goat IgG antibody (SC-2020; Santa Cruz Biotechnology) (dilution 1:5000) in DPBS for 1 hour at room temperature|||||||||||||
Explicit|||12829..12834|80,0,0,0|After|||after|||Temporal.Succession|||||||||||12864..12949|80,0,2;80,0,3,0;80,0,3,1,0;80,0,3,1,1,0,0;80,0,3,1,1,0,1,0;80,0,3,1,1,0,1,1,0;80,0,3,1,1,0,1,1,1|the bands were detected using the enhanced chemiluminescence system (Amersham Italia)||||||||12835..12862|80,0,0,1,0|washing three times in DPBS|||||||||||||
Explicit|||13333..13340|83,0,0,0|Briefly|||briefly|||Restatement.Specification|||||||||||13155..13331|82,0|The assays were performed in a final volume of 20 μl containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM dithiothreitol, 1 mM ethylenediamine tetraacetic acid and 10% glycerol||||||||13342..13977|83,0,2;83,0,3;84,0;85,0;86,0|7 μg cell nuclear extracts, unstimulated or stimulated with testosterone and E2 as previously described, were pre-incubated with 4 μg poly(dI-dC) (Pharmacia, Milan, Italy) as a non-specific competitor, for 10 min at room temperature. End-labelled oligonucleotides (10 fmol, about 30,000 cpm) were then added to each mixture to a final volume of 20 μl and were incubated for an additional 20 min. The bound/retarded complexes were separated from the free probe by electrophoresis on 5% polyacrylamide gels and were visualized by autoradiography of the dried gels. A lane without nuclear extract was also included as the negative control|||||||||||||
Explicit|||13639..13643|84,0,1,0,1,0|then|||then|||Temporal.Precedence|||||||||||13333..13574|83,0|Briefly, 7 μg cell nuclear extracts, unstimulated or stimulated with testosterone and E2 as previously described, were pre-incubated with 4 μg poly(dI-dC) (Pharmacia, Milan, Italy) as a non-specific competitor, for 10 min at room temperature||||||||13576..13638;13644..13736|84,0,0;84,0,1,0,0;84,0,1,0,2;84,0,1,1;84,0,1,2|End-labelled oligonucleotides (10 fmol, about 30,000 cpm) were added to each mixture to a final volume of 20 μl and were incubated for an additional 20 min|||||||||||||
Explicit|||13940..13944|86,0,1,1,0|also|||also|||Conjunction|||||||||||13738..13903|85,0|The bound/retarded complexes were separated from the free probe by electrophoresis on 5% polyacrylamide gels and were visualized by autoradiography of the dried gels||||||||13905..13939;13945..13977|86,0,0;86,0,1,0;86,0,1,2|A lane without nuclear extract was included as the negative control|||||||||||||
Explicit|||14307..14315|88,3,1,1,1,1,0;88,3,1,1,1,1,1,0|prior to|||prior to|||Temporal.Precedence|||||||||||14155..14306|88,0;88,1;88,2;88,3,0;88,3,1,0;88,3,1,1,0;88,3,1,1,1,0|For the super shift assay, 2 μl anti-p65, c-rel and p50 NF-κB subunit antibodies (Santa Cruz Biotechnology) were included in the pre-incubation mixture||||||||14316..14341|88,3,1,1,1,1,1,1|the addition of the probe|||||||||||||
Explicit|||14722..14726|92,0,4,1,3,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||14555..14720|92,0,0;92,0,1;92,0,2;92,0,3,0;92,0,4,0;92,0,4,1,0;92,0,4,1,1|In the present study, after 168 hours we observed a significant growth inhibition of the human monocytic cell line activated with IFN-γ and treated with testosterone||||||||14727..14769|92,0,4,1,3,1,0|compared with the other conditions studied|||||||||||||
Explicit|||15275..15278|97,0,1|and|||and|||Conjunction|||||||||||15227..15274|97,0,0|This marker was analysed by immunocytochemistry||||||||15279..15327|97,0,2|the data were confirmed by western blot analysis|||||||||||||
Explicit|||15454..15458|98,3,0,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||15329..15453|98,0;98,1;98,2;98,3,0,0;98,3,0,1,0;98,3,0,1,1,0;98,3,0,1,1,1,0;98,3,0,1,1,1,1,0|In the testosterone-treated cells, the expression of the PCNA at the immunocytochemistry analysis was found decreased by 24%||||||||15459..15488|98,3,0,2,1,0|compared with untreated cells|||||||||||||
Explicit|||15515..15519|98,3,3,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||15490..15514|98,3,2;98,3,3,0;98,3,3,1,0;98,3,3,1,1,0;98,3,3,1,1,1,0|and was decreased by 40%||||||||15520..15562|98,3,3,2,1,0,0;98,3,3,2,1,0,1,0;98,3,3,2,1,0,1,1,0;98,3,3,2,1,0,1,1,1,0;98,3,3,2,1,0,1,1,1,1|compared with E2-treated cells (Fig. 2a–d)|||||||||||||
Explicit|||15670..15677|99,3,2,3,0|whereas|||whereas|||Contrast|||||||||||15564..15668|99,0,0;99,1;99,2;99,3,0;99,3,1;99,3,2,0;99,3,2,1|Interestingly, the testosterone-treated cells showed staining positivity localized in the cell cytoplasm||||||||15678..15774|99,3,2,3,1|in the untreated and E2-treated cells the PCNA expression was found predominantly in the nucleus|||||||||||||
Explicit|||16088..16092|101,0,1,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||15960..16087|101,0,0;101,0,1,0;101,0,1,1|The annexin V-propidium iodide analysis showed a significant increase of early and late apoptosis in testosterone-treated cells||||||||16093..16123|101,0,1,2,1,0|compared with other conditions|||||||||||||
Explicit|||16229..16233|102,0,3,1,1,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||16125..16228|102,0,0;102,0,1;102,0,2;102,0,3,0;102,0,3,1,0;102,0,3,1,1,0;102,0,3,1,1,1,0;102,0,3,1,1,1,1,0;102,0,3,1,1,1,1,1,0;102,0,3,1,1,1,1,1,1,0|In the absence of staurosporine, the apoptosis was found increased in testosterone-treated cells (9.9%)||||||||16234..16311|102,0,3,1,1,2,1,0,0;102,0,3,1,1,2,1,0,1,0;102,0,3,1,1,2,1,0,1,1;102,0,3,1,1,2,1,0,1,2,0;102,0,3,1,1,2,1,0,1,2,1,0;102,0,3,1,1,2,1,0,1,2,1,1,0;102,0,3,1,1,2,1,0,1,2,1,1,1,0|compared with control untreated cells (2.7%) and with E2-treated cells (3.8%)|||||||||||||
Explicit|||16473..16477|104,0,2,1,1,1,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||16401..16472|104,0,0;104,0,1;104,0,2,0;104,0,2,1,0;104,0,2,1,1,0|In testosterone-treated cells (24.8%) the apoptosis was found increased||||||||16478..16515|104,0,2,1,1,1,1,0,0;104,0,2,1,1,1,1,0,1,0;104,0,2,1,1,1,1,0,1,1,0;104,0,2,1,1,1,1,0,1,1,1,0;104,0,2,1,1,1,1,0,1,1,1,1,0|compared with untreated cells (19.4%)|||||||||||||
Explicit|||16517..16532|105,0|On the contrary|||on the contrary|||Contrast|||||||||||16401..16515|104,0,0;104,0,1;104,0,2,0;104,0,2,1,0;104,0,2,1,1,0;104,0,2,1,1,1,0,0;104,0,2,1,1,1,1,0,0;104,0,2,1,1,1,1,0,1,0;104,0,2,1,1,1,1,0,1,1,0;104,0,2,1,1,1,1,0,1,1,1,0;104,0,2,1,1,1,1,0,1,1,1,1,0|In testosterone-treated cells (24.8%) the apoptosis was found increased when compared with untreated cells (19.4%)||||||||16534..16625|105,2;105,3;105,4,0;105,4,1,0,0;105,4,1,1;105,4,1,2,0;105,4,1,2,1,0;105,4,1,2,1,1|in the E2-treated (15%) cells the apoptosis was decreased versus controls (19.4%) (Fig. 3a)|||||||||||||
Explicit|||16910..16925|108,0|On the contrary|||on the contrary|||Contrast|||||||||||16712..16908|107,0|The immunocytochemistry analysis showed a significant increase of the PARP-cleaved form in testosterone-treated cells compared with other conditions, suggesting an increase of pro-apoptotic events||||||||16927..17115|108,2;108,3;108,4,0;108,4,1|the PARP-cleaved staining showed a decrease (19% versus untreated controls) in E2-treated cells, suggesting a trend of oestrogens in protecting cells from the apoptotic stimuli (Fig. 4a–e)|||||||||||||
Explicit|||17389..17398|111,1,0|therefore|||therefore|||Cause.Result|||||||||||17173..17384|110,0;110,1,0;110,1,1,0;110,1,1,1,0;110,1,1,1,1,0;110,1,1,1,1,1;110,1,1,1,1,2,0,0;110,1,1,1,1,2,1,0,0;110,1,1,1,1,2,1,1|The defined mechanism of NF-κB activation includes the site-specific phosphorylation and subsequent degradation of the inhibitory IκB-α factor, which usually retains the NF-κB factors inactivated in cytosol [27]||||||||17386..17388;17399..17589|111,0,0;111,2|We performed western blot analysis to detect the expression of NF-κB (p65), IκB-α and the IκB-α phosphorylated form (IκB-α-ser 32) in THP-1 cells treated with the different hormone combinations|||||||||||||
Explicit|||17431..17433|111,2,2,0,0|to|||to|||Purpose.Goal|||||||||||17386..17430|111,0,0;111,1,0;111,2,0;111,2,1|We therefore performed western blot analysis||||||||17434..17589|111,2,2,0,1|detect the expression of NF-κB (p65), IκB-α and the IκB-α phosphorylated form (IκB-α-ser 32) in THP-1 cells treated with the different hormone combinations|||||||||||||
Explicit|||17810..17814|112,0,1,1,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||17591..17809|112,0,0;112,0,1,0;112,0,1,1,0;112,0,1,1,1|As shown in western blot analysis (Fig. 5) a decreased expression of NF-κB (p65) and an increased content of IκB-α with a concomitant decrease of the IκB-α phosphorylated form was observed in testosterone-treated cells||||||||17815..17879|112,0,1,1,2,1,0|compared with untreated controls and with E2-treated THP-1 cells|||||||||||||
Explicit|||17967..17970|112,3|but|||but|||Concession.Contra-expectation|||||||||||17881..17966|112,2|the differences between conditions observed with staurosporine treatment were similar||||||||17971..17995|112,4|the expression was lower|||||||||||||
Explicit|||18370..18374|114,0,1,4,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||18212..18368|114,0,0;114,0,1,0;114,0,1,1;114,0,1,2|The concomitant electrophoretic mobility shift assay analysis for the evaluation of the NF-κB DNA binding confirmed an increased binding in E2-treated cells||||||||18375..18456|114,0,1,4,1,0|compared with other conditions with or without staurosporine, as shown in Fig. 6a|||||||||||||
Explicit|||18458..18465|115,0,0,0|Finally|||finally|||Temporal.Precedence|Conjunction||||||||||18212..18456|114,0|The concomitant electrophoretic mobility shift assay analysis for the evaluation of the NF-κB DNA binding confirmed an increased binding in E2-treated cells, when compared with other conditions with or without staurosporine, as shown in Fig. 6a||||||||18467..18638|115,0,2;115,0,3,0;115,0,4|the gel shift assay of nuclear protein extracts from E2-treated cells again showed an increase of the p65 subunit DNA binding (Fig. 6b) when compared with other conditions|||||||||||||
Explicit|||18603..18607|115,0,4,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||18458..18602|115,0,0,0;115,0,1;115,0,2;115,0,3,0;115,0,4,0;115,0,4,1,0;115,0,4,1,1,0;115,0,4,1,1,1,0;115,0,4,1,1,1,1,0;115,0,4,1,1,1,1,1|Finally, the gel shift assay of nuclear protein extracts from E2-treated cells again showed an increase of the p65 subunit DNA binding (Fig. 6b)||||||||18608..18638|115,0,4,2,1,0|compared with other conditions|||||||||||||
Explicit|||18929..18937|119,0,0,0|Moreover|||moreover|||Conjunction|||||||||||18716..18927|118,0,0,0;118,0,1,0;118,0,1,1,0;118,0,1,1,1;118,0,1,1,2,0;118,0,1,1,3;118,0,1,1,1;118,0,1,1,5,0;118,0,1,1,6,0;118,0,1,1,6,1,0;118,0,1,1,6,1,1;118,0,1,1,6,1,2,0;118,0,1,1,6,1,2,1,0;118,0,1,1,6,1,2,1,1|Monocytes/macrophages contribute to the autoimmune process, mainly acting as antigen-processing/presenting cells and sources of inflammatory cytokines, particularly at the level of the synovial tissue in RA [28]||||||||18939..19066|119,0,2;119,0,3|sex hormones can exert local actions (paracrine) in the tissues in which they are formed, including the synovial tissue [29,30]|||||||||||||
Explicit|||19147..19162|121,0,0|On the contrary|||on the contrary|||Contrast|||||||||||19070..19145|120,0|Activated THP-1 cells differentiate into macrophages for long-term cultures||||||||19164..19242|121,0,2;121,0,3|synovial macrophages are characterized by a short life during in vitro culture|||||||||||||
Explicit|||19621..19632|123,2,2|In addition|||in addition|||Conjunction|||||||||||19447..19619|123,0;123,1;123,2,0|The signalling pathways modulating the pro-inflammatory and anti-inflammatory mechanisms seem to involve steroidal hormone receptor activation and the NF-κB complex factors||||||||19634..19728|123,2,4,0;123,2,5|oestrogens may differently regulate NF-κB activation depending on the cell type tested [14,31]|||||||||||||
Explicit|||19735..19744|124,0,1,0|therefore|||therefore|||Restatement.Specification|||||||||||19621..19728|123,2,2;123,2,1;123,2,4,0;123,2,5|In addition, oestrogens may differently regulate NF-κB activation depending on the cell type tested [14,31]||||||||19732..19734;19745..19923|124,0,0,0;124,0,2|E2 increased the expression of markers of cell growth and proliferation, whereas testosterone induced an increase of the PARP-cleaved expression, indicating DNA damage and apoptosis|||||||||||||
Explicit|||19815..19822|124,0,2,3,0|whereas|||whereas|||Contrast|||||||||||19732..19813|124,0,0,0;124,0,1,0;124,0,2,0;124,0,2,1|E2 therefore increased the expression of markers of cell growth and proliferation||||||||19823..19923|124,0,2,3,1;124,0,2,2;124,0,2,5,0|testosterone induced an increase of the PARP-cleaved expression, indicating DNA damage and apoptosis|||||||||||||
Explicit|||19925..19936|125,0,0|In addition|||in addition|||Conjunction|||||||||||19732..19923|124,0|E2 therefore increased the expression of markers of cell growth and proliferation, whereas testosterone induced an increase of the PARP-cleaved expression, indicating DNA damage and apoptosis||||||||19938..20147|125,0,2,0;125,0,1;125,0,4;125,0,5|to support the proliferative role exerted by E2, the THP-1 cells pre-treated with the oestrogens showed a decrease of staurosporine-induced apoptosis when compared with testosterone-treated and untreated cells|||||||||||||
Explicit|||19938..19940|125,0,2,0,0|to|||to|||Purpose.Goal|||||||||||19925..19936;19987..20147|125,0,0;125,0,4;125,0,5|In addition the THP-1 cells pre-treated with the oestrogens showed a decrease of staurosporine-induced apoptosis when compared with testosterone-treated and untreated cells||||||||19941..19985|125,0,2,0,1|support the proliferative role exerted by E2|||||||||||||
Explicit|||20088..20092|125,0,5,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||19925..20087|125,0,0;125,0,1;125,0,2,0;125,0,1;125,0,4;125,0,5,0;125,0,5,1|In addition, to support the proliferative role exerted by E2, the THP-1 cells pre-treated with the oestrogens showed a decrease of staurosporine-induced apoptosis||||||||20093..20147|125,0,5,2,1,0|compared with testosterone-treated and untreated cells|||||||||||||
Explicit|||20149..20160|126,0,0|Furthermore|||furthermore|||Conjunction|||||||||||19925..20147|125,0|In addition, to support the proliferative role exerted by E2, the THP-1 cells pre-treated with the oestrogens showed a decrease of staurosporine-induced apoptosis when compared with testosterone-treated and untreated cells||||||||20162..20523|126,2;126,3|the increased NF-κB p65 expression and the evident NF-κB binding to DNA in E2-treated cells, when compared with untreated cells or with testosterone-treated cells, as well as the increased levels of the IκB-α phosphorylated form, seems to support the major enhancing role exerted by oestrogens on the immune/inflammatory response by activating the NF-κB complex|||||||||||||
Explicit|||20255..20259|126,2,0,1,1,2,0,0|when|||when|||Temporal.Synchronous|Circumstance.Forward Circumstance||||||||||20149..20253;20392..20523|126,0,0;126,1;126,2,0,0;126,2,0,1,0;126,2,0,1,1,0;126,3|Furthermore, the increased NF-κB p65 expression and the evident NF-κB binding to DNA in E2-treated cells seems to support the major enhancing role exerted by oestrogens on the immune/inflammatory response by activating the NF-κB complex||||||||20260..20390|126,2,0,1,1,2,1,0;126,2,1;126,2,2;126,2,3|compared with untreated cells or with testosterone-treated cells, as well as the increased levels of the IκB-α phosphorylated form|||||||||||||
Explicit|||20492..20494|126,3,1,0,1,1,1,3,0|by|||by|||Purpose.Enablement|||||||||||20409..20491|126,3,1,0,1,1,0;126,3,1,0,1,1,1,0;126,3,1,0,1,1,1,1;126,3,1,0,1,1,1,2|the major enhancing role exerted by oestrogens on the immune/inflammatory response||||||||20495..20523|126,3,1,0,1,1,1,3,1,0|activating the NF-κB complex|||||||||||||
Explicit|||20527..20542|127,0|On the contrary|||on the contrary|||Contrast|||||||||||19621..19728|123,2,2;123,2,1;123,2,4,0;123,2,5|In addition, oestrogens may differently regulate NF-κB activation depending on the cell type tested [14,31]||||||||20544..20804|127,2;127,3,0;127,4|the observed positive upregulation of IκB-α exerted by testosterone treatment presumably dampens the pro-inflammatory effects mediated by the NF-κB activation, and therefore might represent a further mechanism by which androgens exert anti-inflammatory effects|||||||||||||
Explicit|||20708..20717|127,4,3,0|therefore|||therefore|||Cause.Claim|||||||||||20527..20702|127,0;127,1;127,2;127,3,0;127,4,0|On the contrary, the observed positive upregulation of IκB-α exerted by testosterone treatment presumably dampens the pro-inflammatory effects mediated by the NF-κB activation||||||||20704..20707;20718..20804|127,4,2;127,4,4|and might represent a further mechanism by which androgens exert anti-inflammatory effects|||||||||||||
Explicit|||20933..20940|128,0,1,3,0,1,1,1,2,0|whereas|||whereas|||Contrast|||||||||||20857..20932|128,0,1,3,0,1,1,0,0;128,0,1,3,0,1,1,1,0;128,0,1,3,0,1,1,1,1,0,0;128,0,1,3,0,1,1,1,1,1,0;128,0,1,3,0,1,1,1,1,1,1,0;128,0,1,3,0,1,1,1,1,1,1,1,0;128,0,1,3,0,1,1,1,1,1,1,1,1|E2 inhibits apoptosis in different cell types (cardiac myocytes and others)||||||||20941..20994|128,0,1,3,0,1,1,1,2,1,0,0;128,0,1,3,0,1,1,1,2,1,1,0;128,0,1,3,0,1,1,1,2,1,1,1,0;128,0,1,3,0,1,1,1,2,1,1,1,1,0;128,0,1,3,0,1,1,1,2,1,1,1,1,1,0,0;128,0,1,3,0,1,1,1,2,1,1,1,1,1,0,1,0;128,0,1,3,0,1,1,1,2,1,1,1,1,1,0,1,1,0;128,0,1,3,0,1,1,1,2,1,1,1,1,1,0,1,1,1|androgens have been found to induce apoptosis [32,33]|||||||||||||
Explicit|||21265..21267|129,0,1,1,0,1,4,0|by|||by|||Purpose.Enablement|||||||||||20998..21263|129,0,0;129,0,1,0;129,0,1,1,0,0;129,0,1,1,0,1,0;129,0,1,1,0,1,1;129,0,1,1,0,1,2|The increased concentrations of oestrogens (and low androgens) recently described at the level of the synovial fluid of RA patients of both sexes [29] seem to support their possible modulator roles on synovial tissue hyperplasia and chronic synovial cell activation||||||||21268..21339|129,0,1,1,0,1,4,1,0|considering the oestrogenic effects on cell proliferation and apoptosis|||||||||||||
Explicit|||21388..21392|130,0,1,1,2,1,0,0|also|||also|||Conjunction|||||||||||20998..21339|129,0|The increased concentrations of oestrogens (and low androgens) recently described at the level of the synovial fluid of RA patients of both sexes [29] seem to support their possible modulator roles on synovial tissue hyperplasia and chronic synovial cell activation, by considering the oestrogenic effects on cell proliferation and apoptosis||||||||21341..21387;21393..21426|130,0,0;130,0,1,0;130,0,1,1,0;130,0,1,1,1,0;130,0,1,1,2,0;130,0,1,1,2,1,1;130,0,1,1,2,1,2;130,0,1,1,2,2,0|These observations have been recently obtained in human breast cancer cells [34]|||||||||||||
Explicit|||21430..21432|131,0,0,0,0|To|||to|||Purpose.Goal|||||||||||21499..21708|131,0,2,0;131,0,2,1,0;131,0,2,1,1,0;131,0,2,1,1,1,0;131,0,2,1,1,1,1,0,0;131,0,2,1,1,1,1,0,1,0;131,0,2,1,1,1,1,0,1,1;131,0,2,1,1,1,1,0,1,2,0;131,0,2,1,1,1,1,0,1,2,1,0,0;131,0,2,1,1,1,1,0,1,2,1,0,1,0;131,0,2,1,1,1,1,0,1,2,1,0,1,1|the pro-inflammatory cytokines (tumour necrosis factor alpha, IL-1β, IL-6) have been found to accelerate the metabolic conversion of oestrogens from androgens by inducing the synovial tissue aromatases [35-37]||||||||21433..21497|131,0,0,0,1|explain increased oestrogen concentrations in RA synovial fluids|||||||||||||
Explicit|||21658..21660|131,0,2,1,1,1,1,0,1,2,0|by|||by|||Purpose.Enablement|||||||||||21499..21657|131,0,2,0;131,0,2,1,0;131,0,2,1,1,0;131,0,2,1,1,1,0;131,0,2,1,1,1,1,0,0;131,0,2,1,1,1,1,0,1,0;131,0,2,1,1,1,1,0,1,1|the pro-inflammatory cytokines (tumour necrosis factor alpha, IL-1β, IL-6) have been found to accelerate the metabolic conversion of oestrogens from androgens||||||||21661..21708|131,0,2,1,1,1,1,0,1,2,1,0,0;131,0,2,1,1,1,1,0,1,2,1,0,1,0;131,0,2,1,1,1,1,0,1,2,1,0,1,1|inducing the synovial tissue aromatases [35-37]|||||||||||||
Explicit|||21710..21726|132,0,0|As a consequence|||as a consequence|||Cause.Result|||||||||||21499..21708|131,0,2,0;131,0,2,1,0;131,0,2,1,1,0;131,0,2,1,1,1,0;131,0,2,1,1,1,1,0,0;131,0,2,1,1,1,1,0,1,0;131,0,2,1,1,1,1,0,1,1;131,0,2,1,1,1,1,0,1,2,0;131,0,2,1,1,1,1,0,1,2,1,0,0;131,0,2,1,1,1,1,0,1,2,1,0,1,0;131,0,2,1,1,1,1,0,1,2,1,0,1,1|the pro-inflammatory cytokines (tumour necrosis factor alpha, IL-1β, IL-6) have been found to accelerate the metabolic conversion of oestrogens from androgens by inducing the synovial tissue aromatases [35-37]||||||||21728..21868|132,0,2;132,0,3,0;132,0,3,1,0;132,0,3,1,1,0;132,0,3,1,1,1;132,0,3,1,1,2;132,0,3,1,1,3,0;132,0,3,1,1,3,1,0,0;132,0,3,1,1,3,1,1;132,0,3,1,1,3,1,2,0;132,0,3,1,1,3,1,2,1|locally increased oestrogen levels might exert activating effects on synovial cell proliferation, including macrophages and fibroblasts [38]|||||||||||||
Explicit|||23922..23927|154,0,1,0,2,0|after|||after|||Temporal.Succession|||||||||||23831..23921|154,0,1,0,0;154,0,1,0,1|Proliferating cell nuclear antigen (PCNA) expression in the cultured human THP-1 cell line||||||||23928..23946|154,0,1,0,2,1|hormonal treatment|||||||||||||
Explicit|||26022..26027|174,0,1,2,0|after|||after|||Temporal.Succession|||||||||||25983..26021|174,0,1,0;174,0,1,1|PARP-cleaved expression in THP-1 cells||||||||26028..26054|174,0,1,2,1|testosterone (T) treatment|||||||||||||
Explicit|||26099..26104|175,0,1,2,0|after|||after|||Temporal.Succession|||||||||||26060..26098|175,0,1,0;175,0,1,1|PARP-cleaved expression in THP-1 cells||||||||26105..26134|175,0,1,2,1|17β-oestradiol (E2) treatment|||||||||||||
